Company Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.
The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth.
It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide.
Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2007 |
| IPO Date | Mar 20, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 167 |
| CEO | John Butler |
Contact Details
Address: 245 First Street, Suite 1400 Cambridge, Massachusetts 02142 United States | |
| Phone | 617 871 2098 |
| Website | akebia.com |
Stock Details
| Ticker Symbol | AKBA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001517022 |
| CUSIP Number | 00972D105 |
| ISIN Number | US00972D1054 |
| Employer ID | 20-8756903 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John P. Butler MBA | Chief Executive Officer, President and Director |
| Dr. Steven Keith Burke M.D. | Senior Vice President of Research and Development and Chief Medical Officer |
| Erik John Ostrowski M.B.A. | Senior Vice President, Chief Financial Officer and Chief Business Officer |
| Richard C. Malabre | Chief Accounting Officer |
| Kimberly Garko | Senior Vice President and Chief Technical Officer |
| Tracey Vetterick | Vice President of Portfolio Strategy and Corporate Administration |
| Mercedes Carrasco | Senior Director of Investor and Corporate Communications |
| Carolyn Rucci | Senior Vice President of Legal, General Counsel and Secretary |
| Meredith Bowman | Senior Vice President and Chief People Officer |
| Nicholas Grund | Senior Vice President and Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | 8-K | Current Report |
| Oct 16, 2024 | 8-K | Current Report |
| Sep 12, 2024 | EFFECT | Notice of Effectiveness |
| Sep 9, 2024 | UPLOAD | Filing |
| Sep 3, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jul 11, 2024 | 8-K | Current Report |
| Jun 24, 2024 | 8-K | Current Report |